McKesson Corporation $MCK Shares Newly Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. purchased a new position in shares of McKesson Corporation (NYSE:MCK) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 675 shares of the company’s stock, valued at approximately $576,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of McKesson during the second quarter valued at approximately $8,156,743,000. State Street Corp increased its position in McKesson by 0.5% during the fourth quarter. State Street Corp now owns 5,780,179 shares of the company’s stock worth $4,746,118,000 after purchasing an additional 29,660 shares during the last quarter. Bank of America Corp DE increased its position in McKesson by 2.4% during the first quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock worth $1,331,552,000 after purchasing an additional 35,916 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in McKesson by 6.8% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,376,276 shares of the company’s stock worth $1,128,945,000 after purchasing an additional 87,513 shares during the period. Finally, Swedbank AB boosted its holdings in McKesson by 13.5% in the 1st quarter. Swedbank AB now owns 1,005,610 shares of the company’s stock valued at $870,215,000 after purchasing an additional 119,327 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Strategic Option Care Health investment: McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for approximately $5.8 billion, including debt. McKesson plans to invest about $1.4 billion for a 49% stake, giving it exposure to the expanding home- and outpatient-infusion market. Option Care shareholders would receive $32.05 per share, representing a premium of roughly 37% before the deal was announced. The transaction remains subject to shareholder and regulatory approvals. CD&R and McKesson ink $5.8bn take-private deal for Option Care Health
• Positive Sentiment: Higher analyst price target: Leerink Partners raised its McKesson target from $1,030 to $1,070 and maintained an “outperform” rating, implying meaningful additional upside based on the referenced trading level. McKesson also received a consensus “moderate buy” recommendation from analysts. Leerink Partners Adjusts Price Target on McKesson to $1,070
• Positive Sentiment: Growth profile remains supportive: Recent coverage highlights McKesson’s above-average earnings growth, favorable Wall Street views and potential benefits from artificial-intelligence adoption. The company’s latest quarter also exceeded consensus estimates for revenue and earnings, while management’s fiscal 2027 EPS guidance supports continued profit growth. Here’s Why McKesson is a Strong Growth Stock
• Neutral Sentiment: The Option Care transaction could strengthen McKesson’s healthcare-services portfolio, but investors will monitor the $1.4 billion capital commitment, integration plans and regulatory approval. McKesson’s thin net margin and elevated valuation also leave less room for execution disappointments.

Analysts Set New Price Targets

Several research firms have recently weighed in on MCK. Barclays increased their price target on shares of McKesson from $925.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, September 4th. UBS Group raised their target price on McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Leerink Partners upped their price target on McKesson from $1,030.00 to $1,070.00 and gave the company an “outperform” rating in a research note on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, McKesson has an average rating of “Moderate Buy” and a consensus target price of $973.19.

McKesson Trading Up 1.9%

McKesson stock traded up $17.15 during trading on Thursday, hitting $927.48. The company had a trading volume of 252,474 shares, compared to its average volume of 936,417. The stock has a market cap of $108.13 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 1.83 and a beta of 0.30. McKesson Corporation has a 1-year low of $723.68 and a 1-year high of $999.00. The company’s 50 day simple moving average is $882.32 and its 200-day simple moving average is $832.73.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 EPS for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The company had revenue of $105.38 billion for the quarter, compared to analysts’ expectations of $103.88 billion. During the same period in the prior year, the firm earned $8.26 earnings per share. The firm’s revenue was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, analysts forecast that McKesson Corporation will post 44.73 earnings per share for the current fiscal year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were issued a dividend of $0.94 per share. This is a positive change from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date was Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 10.06%.

Insider Activity

In other news, Director Bradley E. Lerman sold 301 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of McKesson stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the transaction, the chief accounting officer owned 521 shares of the company’s stock, valued at $464,445.45. This trade represents a 17.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.06% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.